Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 5/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129267 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4ELMNARAB9A | |
| SCHEMBL929481 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4ELMNARAB9A | |
| SCHEMBL1007759 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4ELMNAGAA | |
| SCHEMBL1543531 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4ELMNARAB9A | |
| SCHEMBL6109965 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4EPLCG1MPO | |
| SCHEMBL25347053 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4EPLCG1MPO | |
| SCHEMBL30748563 | 0.80 | CYP11B1 (0.53) | CYP11B1HSD11B1KDM4ELMNARAB9A | |
| Hydrochloric Acid SCHEMBL26104353 | 0.78 | CYP11B1 (0.51) | CYP11B1HSD11B1KDM4EPLCG1MPO | |
| Hydrochloric Acid SCHEMBL3288938 | 0.78 | CYP11B1 (0.51) | CYP11B1HSD11B1KDM4ELMNAGAA | |
| SCHEMBL12490223 | 0.77 | CYP11B1 (0.50) | CYP11B1HSD11B1KDM4EL3MBTL1PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2022079432-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-20210139472-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-13 | — | — | US | disclosed |
| EP-2024358-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008130512-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130524-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008020902-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007133491-A1 | SUBSTITUTED SPIROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139472-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | CYP11B1 127/4885HSD11B1 615/4885KDM4E 4503/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | CYP11B1 106/4885HSD11B1 573/4885KDM4E 4629/4885 |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | CYP11B1 127/4885HSD11B1 615/4885KDM4E 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.